Research Article

PISA Syndrome-Orthopedic manifestation of a neurological disease?

Rajib Dutta*

Published: 05/26/2020 | Volume 4 - Issue 1 | Pages: 038-044

Abstract

Pleurothotonus, commonly known as Pisa Syndrome (PS), is a rare neurological disorder characterized by lateral bending of the trunk with a tendency to lean to one side. This is typically mobile and resolves in supine position. It often presents as an incapacitating symptom of underlying neurodegenerative conditions like Parkinson’s disease, alzheimer’s disease, multisystem atrophy, dementia with Lewy bodies, progressive supranuclear palsy and even subacute sclerosing panencephalitis. It is known to be associated with neuroleptics, dopaminergic agents, valproic acid and lithium. PS is also seen in neurosurgical disorders like subdural hematoma, normotensive hydrocephalus, or as a late complication of pallidotomy in patients with PD. It can present either as an acute emergency or can develop gradually over time.PS tend to happen in coronal plane and can be controlled and managed if diagnosed in early stage. However, a chronic form known as “camptocormia” occurs often in a combined fashion with anteroposterior flexion which can improve to some extent, remain stable or even get worse. Pathophysiologic mechanism is not completely understood. This review will discuss all the updated literatures published in PS in terms of prevalence, pathophysiology, clinical manifestation, and treatment modalities.

Read Full Article HTMLDOI: 10.29328/journal.jnnd.1001032Cite this Article

References

  1. Barone P, Santangelo G, Amboni M, Pellecchia MT, Vitale C. Pisa syndrome in Parkinson’s disease and parkinsonism:  clinical features, pathophysiology, and treatment. Lancet Neurol. 2016; 15: 1063–1074. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27571158
  2. Geroin C, Squintani G, Morini A, Donato F, Smania N, et al. Pisa syndrome in Parkinson’s disease:  electromyographic quantification of paraspinal and non-paraspinal muscle activity. Funct Neurol. 2017; 32: 143–151. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29042003
  3. Tinazzi M, Fasano A, Geroin C. Pisa syndrome in Parkinson disease:  An observational multicenter Italian study.Neurology.2015; 85: 1769–1779. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26491088
  4. Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972; 202: 94–103. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/4115928
  5. Marsili L, Bologna M, Kojovic M, Berardelli A, Espay AJ, et al. Dystonia in atypical parkinsonian disorders. Parkinsonism Relat Disord. 2019; 66: 25–33. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31443953
  6. Woo KA, Yoo D, Ki CS, Lee JY, et al. Spontaneous Pisa syndrome in a patient with early-ons, Azheimer’s disease. Neurol Sci. 2019.
  7. Shinfuku M, Nakajima S, Uchida H, Watanabe K, Kocha H, et al. Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies. Psychiatry Clin Neurosci. 2011; 65: 299. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21507139
  8. Salazar Z, Tschopp L, Calandra C, Micheli F. Pisa syndrome and parkinsonism secondary to valproic acid in Huntington’s disease. Mov Disord. 2008; 23: 2430–2431. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18823027
  9. Solla P, Cannas A, Congia S, Floris G, Aste R, et al. Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson’s disease patient. J Neurol Sci. 2008; 275: 154–156. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18814889
  10. Pandey S, Tomar LR, Tater P. Pisa Syndrome in a Child With Subacute Sclerosing Panencephalitis. JAMA Neurol. 2018; 75: 255–256. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29297046
  11. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus):  epidemiology and management. CNS Drugs.2002; 16: 165–174. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11888337
  12. Todisco M, Pozzi NG, Zangaglia R, Minafra B, Servello D, et al. Pisa syndrome in Idiopathic Normal Pressure Hydrocephalus. Parkinsonism Relat Disord. 2019; 66: 40–44. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31300263
  13. Leon-Sarmiento FE, Pradilla G, Del Rosario Zambrano M. Primary and Reversible Pisa Syndrome in Juvenile Normal Pressure Hydrocephalus. Acta Neuropsychiatr. 2013; 25: 57–60. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686565/
  14. Marchione P, Spallone A, Valente M, Giannone C, De Angelis F, Meco G. Reversible Pisa syndrome associated to subdural haematoma:  case-report. BMC Neurol. 2014; 14: 149. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25123109  
  15. van deWarrenburg BP, Bhatia KP, Quinn NP. Pisa syndrome after unilateral pallidotomy in Parkinson’s disease:  an unrecognised, delayed adverse event? J Neurol Neurosurg Psychiatry. 2007; 78: 329–330. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117655/
  16. Bhattacharya KF, Giannakikou I, Munroe N, Chaudhuri KR. Primary anticholinergic-responsive Pisa syndrome. Mov Disord. 2000; 15: 1285–1287. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11104229
  17. Doherty KM, van de Warrenburg BP, Peralta MC, Moriyama LS, Azulay  JP, et al. Postural deformities in Parkinson’s disease. Lancet Neurol. 2011; 10: 538-549. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21514890
  18. Yassa R, Nastase C, Cvejic J, Laberge G. The Pisa syndrome (or pleurothotonus): prevalence in a psychogeriatric population. Biol Psychiatry. 1991; 29: 942–945. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1675591
  19. Stübner S, Padberg F, Grohmann R, et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry. 2000; 61: 569–574. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10982199
  20. Zannas AS, Okuno Y, Doraiswamy PM. Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study. Pharmacotherapy. 2014; 34: 272–278. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24127392
  21. Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007; 22: 2097–2103. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17685467
  22. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006; 21: 1856–1863. PubMed:  https://www.ncbi.nlm.nih.gov/pubmed/16941460
  23. Baik JS, Kim JY, Park JH, Han SW, Park JH, et al. Scoliosis in patients with Parkinson’s disease. J Clin Neurol. 2009; 5: 91–94. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19587816
  24. Grimes JD, Hassan MN, Trent G, Halle D, Armstrong GW. Clinical and radiographic features of scoliosis in Parkinson’s disease. Adv Neurol. 1987; 45: 353–355. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3825710
  25. Postuma RB, Berg D, Stern M, Poewe W, Olanow  CW, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015; 30: 1591–1601. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26474316
  26. Vitale C, Falco F, Trojano L, Erro R, Moccia M, et al. Neuropsychological correlates of Pisa syndrome in patients with Parkinson’s disease. Acta Neurol Scand. 2016; 134: 101–107. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26427765
  27. Huh YE, Kim K, Chung WH, Youn J, Kim S, et al. Pisa Syndrome in Parkinson’s Disease: Pathogenic Roles of Verticality Perception Deficits. Sci Rep. 2018; 8: 1804. PubMed:  https://www.ncbi.nlm.nih.gov/pubmed/29379091
  28. Castrioto A, Piscicelli C, Perennou D, Krack P, Debu B. The pathogenesis of Pisa syndrome in Parkinson’s disease. Mov Disord.2014; 29: 1100-1107. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24909134
  29. Tinazzi M, Geroin C, Gandolfi M, Smania N, Tamburin S, et al. Pisa syndrome in Parkinson’s disease: An integrated approach from pathophysiology to management. Mov Disord. 2016; 31: 1785–1795. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27779784
  30. Vorovenci RJ, Biundo R, Antonini A. Therapy-resistant symptoms in Parkinson’s disease. J Neural Transm (Vienna). 2016; 123: 19–30. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26410626
  31. Villarejo A, Camacho A, García-Ramos R, Moreno T, Penas M, et al. Cholinergic-dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol. 2003; 26: 119–121. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12782913
  32. Spanaki C, Zafeiris S, Plaitakis A. Levodopa-aggravated lateral flexion of the neck and trunk as a delayed phenomenon of unilateral pallidotomy.Mov Disord. 2010; 25: 655–656. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20131399
  33. Vitale C, Marcelli V, Furia T, Santangelo G, Cozzolino A, et al. Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion. Mov Disord. 2011; 26: 1458–1463. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21465552
  34. Tinazzi M, Juergenson I, Squintani G, Vattemi G, Montemezzi S, et al. Pisa syndrome in Parkinson’s disease: an electrophysiological and imaging study.J Neurol. 2013; 260: 2138–2148. PubMed:  https://www.ncbi.nlm.nih.gov/pubmed/23695587
  35. Tassorelli C, Furnari A, Buscone S, Alfonsi E, Pacchetti C,  et al. Pisa syndrome in Parkinson’s disease: clinical, electromyographic, and radiological characterization.Mov Disord. 2012; 27: 227–235. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21997192
  36. Frazzitta G, Balbi P, Gotti F, Maestri R, Sabetta A, et al. Pisa syndrome in Parkinson’s disease: electromyographic aspects and implication for rehabilitation. Parkinsons Dis. 2015; 2015: 437190. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26682083
  37. Doherty KM, Davagnanam I, Molloy S, Silveira-Moriyama L, Lees AJ. Pisa syndrome in Parkinson’s disease: a mobile or fixed deformity? J Neurol Neurosurg Psychiatry. 2013; 84: 1400–1403. PubMed:  https://www.ncbi.nlm.nih.gov/pubmed/23532719
  38. Hozumi I, Piao YS, Inuzuka T, Matsuyama Z, Yamada Y, et al. Marked asymmetry of putaminal pathology in an MSA-P patient with Pisa syndrome. Mov Disord. 2004; 19: 470–472. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15077247
  39. Solla P, Grau-Rivera O, Gelpi E, Marrosu F, Martí MJ. Pisa syndrome in a patient with pathologically confirmed Parkinson’s disease. Neuropathol Appl Neurobiol. 2016; 42: 654–658. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26999006
  40. Vrtovec T, Pernus F, Likar B. A review of methods for quantitative evaluation of spinal curvature. Eur Spine J. 2009; 18: 593–607. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19247697
  41. Vrtovec T, Pernus F, Likar B. A review of methods for quantitative evaluation of axial vertebral rotation. Eur Spine J. 2009; 18: 1079–1090. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899509/
  42. Cannas A, Solla P, Floris G, Tacconi P, Serra A, et al. Reversible Pisa syndrome in patients with Parkinson’s disease on dopaminergic therapy. J Neurol. 2009; 256: 390–395. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19319462
  43. Miletić V, Radić B, Relja M. Acute pisa syndrome as a neurological emergency. J Neuropsychiatry Clin Neurosci. 2015; 27: e159–e160. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25923868
  44. Yokochi F. Lateral flexion in Parkinson’s disease and Pisa syndrome. J Neurol. 2006; 253 Suppl 7: VII17–VII20. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17131222
  45. Stübner S, Padberg F, Grohmann R, Hampel H, Hollweg M, et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry. 2000; 61: 569–574. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10982199
  46. Suzuki T, Koizumi J, Moroji T, Sakuma K, Hori M, et al. Clinical characteristics of the Pisa syndrome. Acta Psychiatr Scand. 1990; 82: 454–457.
  47. Praharaj SK, Arora M. Pisa syndrome: acute and tardive forms. South Med J. 2007; 100: 853–854.
  48. Martin JP. Curvature of the spine in post-encephalitic parkinsonism. J Neurol Neurosurg Psychiatry. 1965; 28: 395–400. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/5838474
  49. Geroin C, Gandolfi M, Bruno V, Smania N, Tinazzi M. Integrated Approach for Pain Management in Parkinson Disease. Curr Neurol Neurosci Rep. 2016; 16: 28. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26879763
  50. Di Matteo A, Fasano A, Squintani G, Ricciardi L, Bovi T, et al. Lateral trunk flexion in Parkinson’s disease: EMG features disclose two different underlying pathophysiological mechanisms. J Neurol. 2011; 258: 740–745. PubMed:  https://www.ncbi.nlm.nih.gov/pubmed/21079986
  51. Geroin C, Smania N, Schena F, Dimitrova E, Verzini E, et al. Does the Pisa syndrome affect postural control, balance, and gait in patients with Parkinson’s disease? An observational cross-sectional study. Parkinsonism Relat Disord. 2015; 21: 736–741. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25940999
  52. Saifee TA, Edwards MJ. Tardive movement disorders: a practical approach. Pract Neurol. 2011; 11: 341–348.
  53. Schwab FJ, Smith VA, Biserni M, Gamez L, Farcy JP, et al. Adult scoliosis: a quantitative radiographic and clinical analysis. Spine (Phila Pa 1976). 2002; 27: 387–392. PubMed: https://pubmed.ncbi.nlm.nih.gov/11840105
  54. El-Hawary R, Chukwunyerenwa C. Update on evaluation and treatment of scoliosis. Pediatr Clin North Am. 2014; 61: 1223–1241. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25439021
  55. Wunderlich S, Csoti I, Reiners K, Günthner-Lengsfeld T, Schneider C,  et al. Camptocormia in Parkinson’s disease mimicked by focal myositis of the paraspinal muscles. Mov Disord. 2002; 17: 598–600. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12112214
  56. Abboud H, Sivaraman I, Ontaneda D, Tavee J. Camptocormia and Pisa syndrome as manifestations of acute myasthenia gravis exacerbation. J Neurol Sci. 2015; 359: 8–10. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26671078
  57. Doherty KM, Silveira-Moriyama L, Giladi N, Bhatia KP, Parton M, et al. Camptocormia: don’t forget muscle disease in the movement disorder clinic. J Neurol. 2012; 259: 1752–1754. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22349871
  58. Kim JS, Park JW, Chung SW, Kim YI, Kim HT, et al. Pisa syndrome as a motor complication of Parkinson’s disease. Parkinsonism Relat Disord. 2007; 13: 126–128. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16731022
  59. Arora M, Praharaj SK, Sarkar S. Clozapine effective in olanzapine-induced Pisa syndrome. Ann Pharmacother. 2006; 40: 2273–2275. PubMed: https://pubmed.ncbi.nlm.nih.gov/17132806/
  60. Kurtz G, Kapfhammer HP, Peuker B. Pisa syndrome in clozapine therapy [in German]. Nervenarzt. 1993; 64: 742–746. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8278016
  61. Michel SF, Arias Carrión O, Correa TE, Alejandro PL, Micheli F. Pisa Syndrome. Clin Neuropharmacol. 2015; 38: 135–140. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26166239
  62. Walder A, Greil W, Baumann P. Drug-induced Pisa syndrome under quetiapine. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33: 1286–1287. https://www.ncbi.nlm.nih.gov/pubmed/19646500
  63. Kwak YT, Han IW, Baik J, Koo MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet. 2000; 355: 2222. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10881902
  64. Srivanitchapoom P, Hallett M. Camptocormia in Parkinson’s disease: definition, epidemiology, pathogenesis and treatment modalities. J Neurol Neurosurg Psychiatry. 2016; 87: 75–85. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25896683
  65. Zannas AS, Okuno Y, Doraiswamy PM. Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study. Pharmacotherapy. 2014; 34: 272–278. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24127392
  66. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management. CNS Drugs. 2002; 16: 165–174. https://www.ncbi.nlm.nih.gov/pubmed/11888337
  67. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004; 75: 951–957. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1739107/
  68. Tassorelli C, De Icco R, Alfonsi E, Bartolo M, Serrao M, et al. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord. 2014; 20: 1140–1144. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25175601
  69. Dupeyron A, Viollet E, Coroian F, Gagnard C, Renard D, et al. Botulinum Toxin-A for treatment of Pisa syndrome: A new target muscle. Parkinsonism Relat Disord. 2015; 21: 669–670. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25899457
  70. Santamato A, Ranieri M, Panza F, Zoccolella S, Frisardi V, et al. Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson’s disease. J Neurol. 2010; 257: 139–141. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19763384
  71. Upadhyaya CD, Starr PA, Mummaneni PV. Spinal deformity and Parkinson disease: a treatment algorithm. Neurosurg Focus. 2010; 28: E5. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20196652
  72. Capecci M, Serpicelli C, Fiorentini L, Censi G, Ferretti M, et al. Postural rehabilitation and Kinesio taping for axial postural disorders in Parkinson’s disease. Arch Phys Med Rehabil. 2014; 95: 1067–1075. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24508531
  73. Bartolo M, Serrao M, Tassorelli C, Don R, Ranavolo A, et al. Four-week trunk-specific rehabilitation treatment improves lateral trunk flexion in Parkinson’s disease. Mov Disord. 2010; 25: 325–331. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20131386
  74. Kataoka H, Ikeda M, Horikawa H, Ueno S. Reversible lateral trunk flexion treated with a rehabilitation program in a patient with Parkinson’s disease. Parkinsonism Relat Disord. 2013; 19: 494–497. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23274084
  75. Visser JE, Allum JH, Carpenter MG, Esselink RA, Speelman JD,  et al. Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson’s disease. J Neurol. 2008; 255: 205–210. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18274810
  76. Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain. 2007; 130: 1596–1607. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17251240
  77. Shih LC, Vanderhorst VG, Lozano AM, Hamani C, Moro E. Improvement of pisa syndrome with contralateral pedunculopontine stimulation. Mov Disord. 2013; 28: 555–556. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23389993
  78. Ricciardi L, Piano C, Bentivoglio AR, Fasano A. Long-term effects of pedunculopontine nucleus stimulation for Pisa syndrome. Parkinsonism Relat Disord. 2014; 20: 1445–1446. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25455696
  79. Ha Y, Oh JK, Smith JS, Ailon T, Fehlings MG, et al. Impact of Movement Disorders on Management of Spinal Deformity in the Elderly. Neurosurgery. 2015; 77 Suppl 4: S173–S185. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26378355
  80. Suzuki T, Hori T, Baba A, Abe S, Shiraishi H, et al. Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol. 1999; 19: 277–280. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10350039
  81. Fasano A, Di Matteo A, Vitale C, Squintani G, Ferigo L, et al. Reversible Pisa syndrome in patients with Parkinson’s disease on rasagiline therapy. Mov Disord. 2011; 26: 2578–2580. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22170277
  82. Artusi CA, Montanaro E, Tuttobene S, Romagnolo A, Zibetti M, et al. Pisa Syndrome in Parkinson’s Disease Is Associated With Specific Cognitive Alterations. Front Neurol. 2019; 10: 577. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31214112
  83. Fujioka S, Yoshida R, Nose K, Hayashi Y, Mishima T, et al. A new therapeutic strategy with istradefylline for postural deformities in Parkinson’s disease. Neurol Neurochir Pol. 2019; 53: 291-295. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31441493